HS-20093 With or Without Adebrelimab for Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer
Compares HS-20093 with and without adebrelimab in adults with advanced non-squamous lung cancer.
Plain-language title generated from the registry record
Registry title: A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment and have no actionable gene changes.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced or metastatic non-squamous non-small cell lung cancer, confirmed by tissue or cell tests. At least one lesion that can be measured.
- Earlier treatment
- Must have been treated before. Cannot have had treatment targeting B7-H3, topoisomerase I inhibitors, or docetaxel.
- Biomarker or test result
- No actionable genomic alterations.
Main reasons for not taking part
- Active hepatitis B, hepatitis C, HIV, tuberculosis or syphilis
- Untreated or uncontrolled brain metastases, or spinal cord compression
- History of other primary cancers
- Known or suspected interstitial pneumonitis or immune-mediated pneumonitis
- Active autoimmune disease or past severe immune-related side effects
Read by machine on 9 November 2026.
Where in China
- Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hansoh BioMedical R&D Company
- Trial code
- NCT07824882
- Record updated
- 23 October 2026
- Original description
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.Read full original descriptionShow less
A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
Inclusion: Age ≥18 years at the time of informed consent form (ICF) signature, either sex; Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent, and commitment to comply with all requirements specified in this clinical trial protocol; Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC); Presence of at least one measurable target lesion; Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1; Minimum life expectancy >12 weeks; Adequate organ function; Absence of the following active infectious diseases: hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, tuberculosis, or syphilis; Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.
Exclusion: Prior pathological diagnosis of mixed non-small cell lung cancer or any transformed non-small cell lung cancer; Prior or ongoing treatment with any of the following:; Prior or current treatment targeting B7-H3; Prior or current treatment with topoisomerase I inhibitor agents, including antibody-drug conjugates with topoisomerase I inhibitor payloads, etc; Prior treatment with docetaxel monotherapy or in combination with other agents; Persistent adverse reactions caused by prior treatment; Prior occurrence of severe or life-threatening immune-mediated adverse events; History of other primary malignancies; Severe, uncontrolled, or active cardiovascular or cerebrovascular disease; Severe or poorly controlled hypertension; Severe or poorly controlled diabetes mellitus; Clinically significant bleeding symptoms or significant bleeding tendency; Severe infection; History of severe arterial or venous thromboembolic events; Known or suspected interstitial pneumonitis, immune-mediated pneumonitis, or radiation pneumonitis; Participants with active or history of autoimmune disease with potential for recurrence; Presence of any of the following abnormal cardiac findings:; Evidence of currently clinically significant important arrhythmia or ECG abnormality; Presence of risk factors causing QT interval prolongation or arrhythmic events; Untreated brain metastases; uncontrolled brain metastases; presence of leptomeningeal or brainstem metastases; presence of spinal cord compression (identified by radiographic imaging, regardless of symptoms).